|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 39/395 | |
| A61K 47/48 | |||
| A61P 37/00 | |||
| C07K 16/24 |
| (11) | Patento numeris | 1687026 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 04798568.4 |
| Europos patento paraiškos padavimo data | 2004-11-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2006-08-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2008-05-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2004/004850 |
| Data | 2004-11-16 |
| (87) | Numeris | WO 2005/051422 |
| Data | 2005-06-09 |
| (30) | Numeris | Data | Šalis |
| 0327181 | 2003-11-21 | GB | |
| 0417115 | 2004-07-30 | GB |
| (72) |
CHRISTIE, Mark Ian, Celltech R & D Limited, GB
MEAD, Richard James, Celltech R & D Limited, GB
ROBINSON, Martyn Kim, Celltech R & D Limited, GB
RAPECKI, Stephen Edward, Celltech R & D Limited, GB
|
| (73) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
| (54) | METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING IL-17 ACTIVITY |
| METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING IL-17 ACTIVITY |